Gibbs Wealth Management Buys New Position in Sanofi $SNY

Gibbs Wealth Management bought a new stake in shares of Sanofi (NASDAQ:SNY) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 16,217 shares of the company’s stock, valued at approximately $781,000.

Several other institutional investors have also added to or reduced their stakes in SNY. Advisory Services Network LLC boosted its stake in shares of Sanofi by 1.4% during the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after acquiring an additional 210 shares during the last quarter. Savant Capital LLC grew its position in shares of Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock valued at $418,000 after acquiring an additional 225 shares during the period. Wesbanco Bank Inc. increased its stake in shares of Sanofi by 4.9% in the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after purchasing an additional 230 shares in the last quarter. IFG Advisory LLC increased its stake in shares of Sanofi by 2.7% in the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after purchasing an additional 244 shares in the last quarter. Finally, Cohen Investment Advisors LLC raised its holdings in Sanofi by 2.9% in the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after purchasing an additional 263 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SNY has been the topic of several analyst reports. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Argus raised Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Morgan Stanley set a $49.00 price objective on Sanofi in a research note on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price for the company. in a report on Monday, April 20th. Finally, Wall Street Zen cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Trading Down 0.0%

Shares of Sanofi stock opened at $43.35 on Friday. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The company has a market capitalization of $105.10 billion, a P/E ratio of 12.11, a P/E/G ratio of 1.10 and a beta of 0.34. The company has a fifty day moving average of $43.44 and a 200 day moving average of $45.36.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.